Gaedigk A - Search Results

1

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY. Yang X, et al. Among authors: gaedigk a. Genome Res. 2010 Aug;20(8):1020-36. doi: 10.1101/gr.103341.109. Epub 2010 Jun 10. Genome Res. 2010. PMID: 20538623 Free PMC article.

2

Epitope mapping studies with human anti-cytochrome P450 3A antibodies.

Leeder JS, Gaedigk A, Lu X, Cook VA. Leeder JS, et al. Among authors: gaedigk a. Mol Pharmacol. 1996 Feb;49(2):234-43. Mol Pharmacol. 1996. PMID: 8632755

3

Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase.

Gaedigk A, Leeder JS, Grant DM. Gaedigk A, et al. DNA Cell Biol. 1997 Nov;16(11):1257-66. doi: 10.1089/dna.1997.16.1257. DNA Cell Biol. 1997. PMID: 9406998

4

Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions.

Leeder JS, Lu X, Timsit Y, Gaedigk A. Leeder JS, et al. Among authors: gaedigk a. Pharmacogenetics. 1998 Jun;8(3):211-25. doi: 10.1097/00008571-199806000-00004. Pharmacogenetics. 1998. PMID: 9682267

5

Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.

Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Henne KR, et al. Among authors: gaedigk a. J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):143-8. doi: 10.1016/s0378-4347(98)00099-1. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9686881

6

High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data.

Bradford LD, Gaedigk A, Leeder JS. Bradford LD, et al. Among authors: gaedigk a. Psychopharmacol Bull. 1998;34(4):797-804. Psychopharmacol Bull. 1998. PMID: 10513455 Review.

7

Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.

Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Gaedigk A, et al. Can J Physiol Pharmacol. 2001 Oct;79(10):841-7. Can J Physiol Pharmacol. 2001. PMID: 11697742

8

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.

Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A. Marcucci KA, et al. Among authors: gaedigk a. Drug Metab Dispos. 2002 May;30(5):595-601. doi: 10.1124/dmd.30.5.595. Drug Metab Dispos. 2002. PMID: 11950793

9

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.

Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Gaedigk A, et al. Clin Pharmacol Ther. 2002 Jul;72(1):76-89. doi: 10.1067/mcp.2002.125783. Clin Pharmacol Ther. 2002. PMID: 12152006 Clinical Trial.

10

CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism.

Gaedigk A, Ryder DL, Bradford LD, Leeder JS. Gaedigk A, et al. Clin Chem. 2003 Jun;49(6 Pt 1):1008-11. doi: 10.1373/49.6.1008. Clin Chem. 2003. PMID: 12766015 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters